GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels, has announced the upcoming release of its sensitive PCR tests to monitor the coronavirus Omicron variant, B.1.1.529.
| FORT COLLINS, Colo., Dec. 8, 2021 /PRNewswire/ -- GT Molecular, a company providing multiplexed, ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels, has announced the upcoming release of its sensitive PCR tests to monitor the coronavirus Omicron variant, B.1.1.529.
GT Molecular releases two offerings for the detection of the SARS-CoV-2 Omicron variant The Omicron variant which was designated a “variant of concern” by the World Health Organization (WHO) is by far the most divergent variant with more than 30 mutations in the spike protein. The virus was first identified in South Africa and has now been reported in dozens of countries around the world. The WHO has reported that preliminary findings suggest a higher risk of transmission compared to other variants of concern. Two offerings are available for the detection of the Omicron, B.1.1.529 variant:
These new offerings underline the GT Molecular’s commitment to supporting the world’s pandemic response by rapidly providing highly sensitive and specific assays for monitoring new SARS-CoV-2 variants. About GT Molecular GT Molecular is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests. GTM’s molecular app technology is an easy-to-use, end-to-end solution for rapid deployment and provides reliable and consistent measurements while detecting as little as 1-3 molecules of target nucleic acid. The company has a growing catalog of molecular assays that includes SARS-CoV-2 multi-variant tests, cancer panels, multiplexed pathogen panels for clinical labs and quantitative standards. ORDER & INFORMATION: info@gtmolecular.com
SOURCE GT Molecular |
View original content: